Related Experiment Video
Updated: Jul 6, 2026
High-throughput Fluorometric Measurement of Potential Soil Extracellular Enzyme Activities
Published on: November 15, 2013
[Not Available]
M D Gutiérrez-Tarango1, A Berber
1Pediatrics Service of `Pensiones Civiles del Estado de Chihuahua', Chihuahua City, Chihuahua, Mexico.
Insights
Broncho-Vaxom, a bacterial extract, significantly reduced respiratory infections in children. This treatment led to fewer sick days and less need for antibiotics, offering a safe option for preventing recurrent respiratory issues.
Area of Science:
- Pediatrics
- Immunology
- Pharmacology
Background:
- Recurrent respiratory tract infections (RRTIs) are a common concern in children.
- Effective preventive strategies are needed to reduce the burden of RRTIs.
Purpose of the Study:
- To evaluate the efficacy of bacterial extract OM-85 BV (Broncho-Vaxom) in preventing chronic, recurrent respiratory diseases in children.
- To compare Broncho-Vaxom with conventional management for RRTIs.
Main Methods:
- An open, prospective trial enrolled 61 children (1-11 years) with at least three RRTIs in six months.
- The treatment group (30 children) received Broncho-Vaxom for three months, while the control group (31 children) received conventional management.
- A six-month follow-up period monitored infection rates and treatment outcomes.
Main Results:
- Children treated with Broncho-Vaxom experienced a significant reduction in the average number of infections (2.25 vs. 4.68).
- The Broncho-Vaxom group had fewer days of illness (11.8 vs. 28.06), required fewer antibacterial treatments (1.1 vs. 2.52), and less additional conventional drug use (2.17 vs. 4.39).
- Fewer treatment days were observed in the Broncho-Vaxom group (14.27 vs. 30).
Conclusions:
- Broncho-Vaxom demonstrated significant efficacy in reducing the incidence of respiratory tract infections in susceptible children.
- The bacterial extract is a practical and safe therapeutic option for preventing RRTIs.
- This study supports the use of Broncho-Vaxom as an adjunct therapy in pediatric respiratory health.
Abstract:
An open, prospective trial was conducted to compare the efficacy of a bacterial extract (OM-85 BV) [;Broncho-Vaxom'] vs conventional management in the prevention of chronic, recurrent respiratory diseases in children. 61 children aged between 1 and 11 years who had presented three or more respiratory tract infections in the last 6 months were enrolled. 30 children (mean age 4.1 +/- 2.7 years) received one capsule a day of Broncho-Vaxom, 10 days a month, for 3 consecutive months, and 31 (mean age 3.8 +/- 2.0 years) received no Broncho-Vaxom and served as a control group. During the 6-month follow-up period, patients treated with Broncho-Vaxom showed a significant reduction in the average number of infections (2.25 +/- 0.58 vs 4.68 +/- 0.94, p < 0.05); they were ill a lesser number of days (11.8 +/- 3.67 vs 28.06 +/- 6.72, p < 0.05), were exposed to fewer antibacterial treatments (1.1 +/- 0.76 vs 2.52 +/- 0.85, p < 0.05), required less additional treatment with conventional drugs (2.17 +/- 0.59 vs 4.39 +/- 0.88, p < 0.05), and spent fewer days under treatment (14.27 +/- 7.27 vs 30 +/- 6.49, p < 0.05). In conclusion, Broncho-Vaxom appears to be a practical, safe option for lowering the incidence of respiratory tract infections in susceptible children.
